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Abstract
Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently
there has been rising interest in deploying mass spectrometric (MS) methods of detection for measuring IGF1. However,
widespread clinical adoption of any MS-based IGF1 assay will require increased throughput and speed to justify the costs of
analyses, and robust industrial platforms that are reproducible across laboratories. Presented here is an MS-based
quantitative IGF1 assay with performance rating of .1,000 samples/day, and a capability of quantifying IGF1 point
mutations and posttranslational modifications. The throughput of the IGF1 mass spectrometric immunoassay (MSIA)
benefited from a simplified sample preparation step, IGF1 immunocapture in a tip format, and high-throughput MALDI-TOF
MS analysis. The Limit of Detection and Limit of Quantification of the resulting assay were 1.5 mg/L and 5 mg/L, respectively,
with intra- and inter-assay precision CVs of less than 10%, and good linearity and recovery characteristics. The IGF1 MSIA
was benchmarked against commercially available IGF1 ELISA via Bland-Altman method comparison test, resulting in a slight
positive bias of 16%. The IGF1 MSIA was employed in an optimized parallel workflow utilizing two pipetting robots and
MALDI-TOF-MS instruments synced into one-hour phases of sample preparation, extraction and MSIA pipette tip elution, MS
data collection, and data processing. Using this workflow, high-throughput IGF1 quantification of 1,054 human samples was
achieved in approximately 9 hours. This rate of assaying is a significant improvement over existing MS-based IGF1 assays,
and is on par with that of the enzyme-based immunoassays. Furthermore, a mutation was detected in ,1% of the samples
(SNP: rs17884626, creating an ART substitution at position 67 of the IGF1), demonstrating the capability of IGF1 MSIA to
detect point mutations and posttranslational modifications.
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Introduction
Insulin-like growth factor 1 (IGF1) is an important biomarker
for the management of growth hormone disorders. IGF1 is
produced by the IGF1 gene located on chromosome 12 in
humans, and is a critical intermediary involved in cell growth,
differentiation, and transformation [1,2]. Human IGF1 is a 70
amino-acid protein containing three intra-disulfide bonds, with a
mass of 7648.7 Da. Serum IGF1 reference values in healthy
individuals are 20–600 mg/L [3,4]. The majority of IGF1
produced acts as an endocrine hormone via secretion from the
liver, but the molecule can also serve as a paracrine hormone in
certain tissues including cartilaginous cells, and even in autocrine
mode as an oncogene [5–7]. IGF1 exerts its effects by binding to
the IGF1 receptor on target tissues. In blood, 99% of the IGF1 is
bound to IGFBPs (Insulin-like growth factor binding proteins),
with 80% of circulating IGF1 in a ternary complex consisting of
one molecule of IGF1, one molecule of IGFBP3, and one molecule
of an acid labile subunit [4,8–10]. As such, the presentation of
circulating IGF1 has created the need for methods to disrupt these
complexes for accurate IGF1 quantification. For over the past
thirty years, IGF1 has been generally quantified using including
radioimmunoassay (RIA), immuno-radiometric assay (IRMA),
enzyme-linked immunosorbent assay (ELISA), and chemilumines-
cence [3,11,12]. These methods employ various sample prepara-
tion steps to disrupt and remove IGFBPs (and thus present free
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IGF1 for assaying), including low pH, size exclusion chromatog-
raphy, and acid-ethanol extraction. Some methods also include an
addition of IGFBP blocking agent, typically IGF2 [11]. Because of
these variations, commercial assays have not provided comparable
measurements of serum IGF1 [13].
Since 2001 there has been a rising interest in deploying mass
spectrometric methods of detection for measuring IGF1 [14,15].
Such methods can be categorized as either bottom up (enzymatic
digestion followed by analyzing surrogate peptides representative
of IGF1) or top-down (no digestion – the intact IGF1 is analyzed
directly) and in some instances use immunoprecipitation as a
separation step prior to detection. In 2004, our group employed a
top-down mass spectrometric immunoassay (MSIA) to quantify
IGF1 in human samples [16]. The approach employed a novel
sodium dodecyl sulfate (SDS) treatment to disrupt IGFBPs prior to
immunoaffinity capture of IGF1, followed by direct detection of
intact IGF1 using MALDI-TOF mass spectrometry. Endogenous
IGF1 was quantified by introducing a mass-shifted IGF1 analog
(internal standard) into samples prior to any processing. The
internal standard was present through the entirety of the
workflow/analysis, ultimately registering as a mass-resolved signal
in the mass spectra that was used for IGF1 signal normalization
and quantification (via a working curve method). In 2008, Thevis
et. al. utilized immunoprecipitation coupled to liquid chromatog-
raphy/electrospray ionization tandem mass spectrometry (LC/
MS) to quantify IGF1 and related analogues [17]. This approach
monitored product ions arising from IGF1 terminal peptide
fragment dissociations (the molecule was fragmented from its
intact form, thus limiting the sequence coverage due to the three
remaining intact disulfide bonds). Recently, non-immunoprecip-
itation MS-based methods for IGF1 quantification have found
traction. In 2009, Kay et. al implemented an acetonitrile
precipitation extraction with a bottom-up LC/MS/MS SRM
approach [18]. This approach monitored MS3 ions of the n-
terminal IGF1 fragment (residues 1–21), provided a dynamic
range of 16–2000 mg/L, and had CV’s ,13%. Solid-phase
extraction methods have also been found to work for IGF1
quantification. Bystrom et. al. demonstrated top-down IGF1
Table 1. Parallel workflow for the IGF1 assay.
8am 9am 10am 11am 12pm 1pm 2pm 3pm 4pm 5pm
Phases (60 minutes each);
Number of individuals involved Plate #
Sample Preparation; 1 1,2 3,4 5,6 BREAK 7,8 9,10 11,12
Immunoprecipitation and
Elution; 1
1,2 3,4 5,6 BREAK 7,8 9,10 11,12
MS Data Collection; 2 1,2 3,4 BREAK 5,6 7,8 9,10 11,12
Data Processing; 1 1,2 BREAK 3,4 5,6 7,8 9,10 11,12
doi:10.1371/journal.pone.0092801.t001
Fig. 1. Mass spectra from a normal individual (A) and an individual with a single nucleotide polymorphism (B). m/z values refer to
the average mass [M+H]+. A) Native IGF1 was detected (observed 7649.99 m/z, theoretical 7649.71) along with a putative glycosylated variant
(labeled with *; observed 8346.90 m/z, theoretical unknown). B) Both IGF1 (observed 7649.75 m/z, theoretical 7649.71) and IGF1 A67T (observed
7679.75 m/z, theoretical 7679.71) were detected as well as their respective putative glycosylated variants (observed 8349.35 m/z, theoretical
unknown and observed 8379.15 m/z, theoretical unknown).
doi:10.1371/journal.pone.0092801.g001
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quantification via solid phase extraction coupled to narrow mass
extraction (via Q-TOF) of a single IGF1 isotope in the 7+ charge
state (m/z 1093.5209) provided excellent analytical metrics (CVs
,5.2%, LOD 3.7 mg/L) [19]. Also, Kay et. al. further refined their
approach, now introducing solid phase extraction (SPE) on the
front end of the workflow, and expanded the method to monitor
two IGF1 tryptic fragments (1–21, and 38–50) [20]. Each of these
approaches has their own merits and taken altogether they clearly
show the value of IGF1 quantification with MS detection.
However, beyond providing unambiguous detection of IGF1
with high analytical performance, widespread clinical adoption of
any MS-based IGF1 assay will require increased throughput and
speed to justify the costs of the analyses (primarily due to unit time
and consumables), robust industrial platforms that are reproduc-
ible across laboratories (turn-key systems), and the long-term
sustainability of supply chains associated with the IGF1 assay (as
well as any additional assays). Moreover, and mindful of the ability
of mass spectrometry to readily detect molecular variants of a
targeted protein [21], the current state of IGF1 mass spectrometric
assays could also benefit from enhanced configurations that
account for the protein microheterogeneity across populations.
Such heterogeneity could feasibly cause currently employed top-
down and bottom-up MS approaches to fail, if a patient is
phenotypically heterozygous via a single nucleotide polymor-
phism, or if N- or C-terminal truncations alter the m/z signals that
are being monitored in LC/MS. Also, such protein heterogeneity
could have yet-undiscovered pathophysiological implications and
potential clinical utility.
In this work, we present an MS-based quantitative IGF1 assay
that meets all of the above mentioned requirements through
achieving these two goals: 1) To rigorously quantify IGF1 in
human plasma samples at a rate of .1,000 samples/day, in order
to factually benchmark time and economic considerations
associated with translating such targeted mass spectrometric assays
from research laboratories to clinical deployment, and 2) To
accommodate IGF1 heterogeneity discovered from analysis of
large populations in order to intelligently design IGF1 mass
spectrometric assays that avoid error due to structural variants (or
enable study of the variants in alternate disease situations). To the
best of our knowledge, neither of these aspects of assay/biomarker
translation has been previously put to test and reported on to any
substantial degree.
Materials and Methods
Human plasma samples
For development of the assay, a bulk quantity (.100 mL) of
healthy human EDTA plasma from an individual female donor
was purchased from ProMedDX (Norton, MA). One thousand
and fifty-four (1,054) human EDTA plasma samples were
obtained, with Arizona State University Bioscience IRB approval
(Protocol No. 0808003133, Study Title: Oxidative stress in
persons with impaired glucose tolerance). The participants signed
a written informed consent form that was approved by the IRB.
Samples were collected in the following fashion: 20mL of blood
was collected into two 10 mL lavender top tubes with EDTA
preservative. Tubes were gently inverted several times to prevent
the formation of a clot. Samples were then centrifuged at 4uC for
15 minutes at 1300 G (Approx. 3000–4000 rpm). This was
completed within 30 minutes of collection time. Using a transfer
pipette, plasma was then aliquoted into two 6 mL purple-capped
(plasma circled) plastic screw capped cryovials. Samples were
frozen within 30 minutes at 280uC after being collected and
centrifuged. All samples were then shipped on dry ice and received
numbered and without any identifiers. Upon arrival, the samples
were thawed and immediately aliquoted into 96 well plates, sealed,
and frozen at 280uC.
Reagents
Polyclonal rabbit anti-human IGF1 affinity purified antibody
(Cat. No. PA0362), recombinant human IGF1 (Cat. No. C-
RI500c), and recombinant human LR3-IGF1 (Cat. No. LRM001)
were obtained from Cell Sciences (Canton, MA). Of note,
recombinant human IGF1 was the immunogen used to create
the polyclonal antibody. Custom MSIA Pipette Tips (Cat.
No. 991CUS02), acetonitrile (A954-4), and phosphate buffered
saline (PBS, 28372) were obtained from Thermo Fisher Scientific
(San Diego, CA). Sinapic acid (Cat. No. 85249), sodium dodecyl
sulfate (SDS, Cat. No. 436143), bovine serum albumin (BSA, Cat.
No. A4503-10G), trifluoroacetic acid (TFA, Cat. No. 299537),
and TWEEN 20 (Cat. No. P7949) were obtained from Sigma-
Aldrich (St. Louis, MO). An IGF1 ELISA Kit (Cat. No. RMEE20)
was purchased from Biovendor (Asheville, NC). The polypropyl-
ene 96-micro titer plates (Cat. No. 651201) were purchased from
Greiner Bio-One. Covers used to seal plates (Cat. No. 60941-074)
were purchased from VWR.
Preparation of standards and analytical samples
For the standard curve generation, the IGF1 stock (1 g/L) was
serially diluted to 1,500; 1,000; 500; 100; 25; 10; and 5 mg/L, with
100 mM PBS containing 1 g/L BSA (standards buffer). The
internal reference standard (LR3-IGF1, 1 g/L) was also serially
diluted in standards buffer to a final concentration of 500 mg/L.
The human plasma samples and the IGF1 standards were pre-
aliquoted into twelve 96-well microplates (40 mL per well) and
stored at 280uC prior to use.
Mass Spectrometric Immunoassay parallel workflow
Steps 1–4 described below were run in a parallel workflow that
processed two microplates (192 samples) at-a-time, in an
overlapping sequence configuration, resulting in a total processing
time of 9 hours for all 12 microplates.
Step 1: Sample preparation. On the day of analysis, the
first two microplates containing 40 mL of human plasma (or
Fig. 2. An example of a standard curve for the IGF1 MSIA.
Plotted are the peak area ratios of IGF1/LR3-IGF1 over the standards
concentrations. Solid line: linear fit with R2 = 0.99, SEE = 0.69. Dotted
lines: 95% prediction intervals. The average r2 for the twelve standard
curves was 0.98 and the range was 0.97–0.99.
doi:10.1371/journal.pone.0092801.g002
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standards) per well were thawed at room temperature (15 minute
thaw time). Using an eight-channel electronic pipettor, a 20 mL
aliquot of internal reference standard (500 mg/L LR3-IGF1) and a
100 mL aliquot of sample buffer (100 mM PBS w/0.3% (w/v) SDS
and 0.1% TWEEN 20) were added to each well, for a total
analytical volume of 160 mL in each well. The microplates were
then shaken at room temperature for 30 min on an orbital shaker,
at 1,000 rpm, to dissociate the IGF1 from the IGFBPs. Total
preparation time: ,60 minutes.
Step 2: Immunoaffinity retrieval and elution. The
immunoaffinity retrieval of IGF1 and LR3-IGF1 from the samples
was performed using MSIA-Tips derivatized with the IGF1
antibody. Preparation of affinity pipettes were done as previously
described for other mass spectrometric immunoassays [22]. Two
sets of 96 IGF1 MSIA-tips were mounted on two Multimek 96
automated 96-channel pipettors (Beckman Coulter, Brea, CA) and
each set of tips were first rinsed with assay buffer (100 mM PBS
w/0.1% TWEEN 20), with 10 cycles (1 cycle consisting of a single
aspiration and dispense of a 125 mL volume, ,3 s), from a single
150 mL buffer aliquot placed in the well of a microplate. Next, the
MSIA-Tips were immersed into the wells of the microplates
containing the samples, and 100 aspirations and dispense cycles
were performed (125 mL volumes each), allowing for simultaneous
affinity capture of IGF1 and LR3-IGF1. The MSIA-Tips were
then rinsed with assay buffer (100 cycles) from another microplate,
and twice with water (10 cycles each) from two more microplates
(125 mL volumes aspiration and dispenses, from 150 mL placed in
each well). The captured proteins were eluted from the MSIA-
Tips by drawing 4 mL of MALDI matrix solution (saturated
aqueous solution of sinapic acid, in 33% (v/v) acetonitrile, 0.45%
(v/v) trifluoroacetic acid) into the tip and eluting it onto a 96-well
format MALDI target. The MALDI targets were air dried for 20
minutes. Total extraction and drying time: ,60 minutes.
Step 3: MS data collection. MALDI-TOF MS was
performed using an Ultraflex III MALDI-TOF mass spectrometer
and an Autoflex III MALDI-TOF mass spectrometer (Bruker
Daltonics, Billerica, MA). Both instruments were used in linear
mode. With the Ultraflex, positive ion, delayed-extraction mode
was used with ‘ionsource 1’ at 25.00 kV, ‘ion source 2’ at
23.30 kV, lens at 5.75 kV, 10 ns delayed extraction, deflection
signal suppression up to m/z 500, and 1 GS/s sample rate. With
the Autoflex, positive ion, delayed-extraction mode was used with
‘ionsource 1’ at 20.00 kV, ‘ion source 2’ at 18.50 kV, lens at 8 kV,
130 ns delayed extraction, deflection signal suppression up to m/z
4000, and 1 GS/s sample rate. On both instruments, at least six
thousand laser-shots were signal averaged for each mass spectrum
to ensure good ion counting statistics (approximately 30 seconds
per spot). Spectra were externally calibrated with a mixture of 4
proteins, supplied by Bruker (Cat. No. 208241). Total processing
time: ,60 minutes.
Step 4: Data Processing. Individual mass spectra were
baseline subtracted (TopHat algorithm) and smoothed (Savitzky-
Golay algorithm; width = 0.2 m/z; cycles = 1) prior to peak
integration using the flexAnalysis 3.0 software (Bruker Daltonics).
All peaks representing LR3 IGF1, native IGF1, and IGF1 variants
were integrated baseline-to-baseline (using Intrinsic Bioprobes Inc.
Zebra 1.0 software) and tabulated in a spreadsheet for quantifi-
cation. Total processing time: ,60 minutes.
IGF1 Quantification
All samples (plasma and standards) were fortified with a
constant amount of the internal reference standard (IRS)
(62.5 mg/L LR3 IGF1). For each microplate, a standard curve
was generated by plotting the IGF1/LR3-IGF1 peak areas against
the concentration of the IGF1 standards, and the data was fitted
with a linear trend line using Sigma Plot (Systat Software, San
Jose, CA). This standard curve was then utilized to determine the
Table 2. Intra-and inter-assay precision.
Intra-assay CVs Inter-assay CV
Sample 1 2 3 4 5 6 Sample 1 2
STDEVP: 10.9 11.8 11 19.5 7.7 19.5 STDEVP: 9.31 5.91
MEAN (mg/L): 156 162 140 216 203 204 MEAN (mg/L): 152.6 207.8
CV (%): 6.96 7.28 7.85 9.03 3.79 9.75 CV (%): 6.1 2.85
doi:10.1371/journal.pone.0092801.t002
Table 3. Assay linearity.
Sample Dilution Observed Expected Recovery
mg/L mg/L O/E %
1 306
2x 146 153 95.2
4x 72.7 76.60 94.9
8x 39.1 38.30 102
2 239
2x 131 120 110
4x 57.3 59.7 95.9
8x 34.2 29.9 115
doi:10.1371/journal.pone.0092801.t003
Table 4. Spiking recovery.
Sample Observed Expected Recovery
mg/L mg/L O/E%
1 112
244 259 94.1
301 339 88.9
464 419 111
2 95.5
212 233 91.0
346 313 111
414 393 106
doi:10.1371/journal.pone.0092801.t004
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absolute concentration of IGF1 and its variants in the human
plasma samples present in the same microplate.
Results and Discussion
The overall workflow for IGF1 quantification of over one
thousand samples, utilizing two pipetting robots and two MALDI-
TOF-MS instruments synced into one-hour phases of sample
preparation, extraction and MSIA pipette tip elution, MS data
collection, and data processing, is shown in Table 1. Using this
workflow, IGF1 was quantified in 1,054 human samples (frozen
plasma – to – data) in approximately 9 hours. This rate of assaying
is a significant improvement over existing MS-based IGF1 assays
[19,20], and is on par with that of the enzymatic immunoassays
[11]. Although the assay methodology utilized in this work was
adopted from our previous work [16], minor modifications were
incorporated to achieve the high-throughput analysis while still
exploring the unknown molecular landscape of IGF1 protein
heterogeneity in large populations should novel variant forms of
IGF1 present themselves.
An important feature of the quantitative IGF1 assay is the
addition of the IRS at the beginning of the sample preparation. It
is important that the IRS goes through the same processing as does
the protein target that is being assayed, to control for possible
losses during these processes. Mass-shifted protein analogs may be
used as internal standards for MALDI-TOF MS quantification,
wherein the internal standard and target protein are captured
together using the same antibody [16,23,24]. The role of internal
Fig. 3. Histogram of IGF1 concentrations determined by MSIA for 1054 EDTA treated human plasma samples.
doi:10.1371/journal.pone.0092801.g003
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standard was fulfilled by Long Arginine 3 IGF1 (LR3-IGF1), an
acting molecular variant of IGF1 with a mass of 9,111 Da which
contains an arginine substitution at position 3, along with a 13
amino acid n-terminal extension [25]. The mass-shift of
+1,462 Da relative to the native IGF1 (7,649 Da) provided a
sufficient ‘‘open m/z window’’ to discover unknown variants of
IGF1 (should they appear in the mass spectra). Of course, these
variants would have to be retrieved by the IGF1 antibody
immobilized in the MSIA-Tips. This was made possible by the use
of a polyclonal IGF1 antibody, which can capture multiple
variants (i.e. LR3-IGF1 and the variants described below) to be
unambiguously detected via mass spectrometry. Future studies
may precisely determine whether or not the polyclonal antibody
has a preference for a specific region or confirmation of the IGF1
molecule to ensure all variants are being captured.
Fig. 1 shows two IGF1 MSIA mass spectra representative of the
individuals within this study. The first one is that observed from
the majority of the samples (‘‘normal IGF1’’), while the other
represents heterozygous IGF1 detected in approximately 0.9% of
the samples, manifesting itself through the appearance of an
additional IGF1 signal at +29.7 Da. The mutation giving rise to
the heterozygous IGF1 has previously been reported [26] and
arises from a single nucleotide polymorphism creating an ART
substitution at position 67 (IGF1 SNP: rs17884626). This mutation
is observed primarily in individuals with African descent [26]. The
mutation was confirmed by sequencing of the DNA purified from
the positive plasma [27].
Another possible variant of IGF1 was identified from the data,
at a mass of ,700 Da higher than IGF1. Interestingly, this signal
was also detected in all nine heterozygous samples as a twin-peak
accounting for both native and the ART 67 form of IGF1 (with a
mass shift of +29.7 Da). Because of the low relative abundance of
this variant, we were unable to determine its exact identity via
MS/MS, however, the mass shift potentially corresponds to
glycosylation. Further investigations are underway to evaluate this
IGF1 variant. Because of the ubiquitous detection of this signal in
both homozygous and heterozygous samples, its absence in
negative controls, and the use of specific antibody for IGF1
retrieval, it is presumed that this is a glycosylated isoform of IGF1.
Lastly, IGF2 and des-Ala IGF2 [28] were also distinctly detected
in all mass spectra due to the cross-reactive specificity imparted by
the IGF1 antibody. Of note, other top-down IGF1 MS approaches
are not configured for detecting variants that are not previously
known (e.g. the variants described above).
In all, the IGF1 MSIA standard curves demonstrated excellent
linearity (dynamic range of 103) across the normal IGF1
physiological range (5–500 mg/L; average r2 = 0.99 for the twelve
standard curves), and across higher concentration ranges associ-
ated with conditions such as acromegaly (5–1,500 mg/L; average
r2 = 0.98 for the twelve standard curves). An example of a working
curve is shown in Fig. 2. The Limit of Detection (defined at S/
N=3) and Limit of Quantification (defined at S/N=10) were
determined to be 1.5 mg/L and 5 mg/L, respectively. The intra-
assay precision (within-run) was determined by analyzing six
plasma samples, in triplicate, each with a single standard curve.
The inter-assay precision (run-to-run) was determined by analyz-
ing two plasma sample three times, on different days, with separate
standard curves each time. The results are shown in Table 2, and
indicate CVs of less than 10%. To determine the linearity of the
assay, plasma samples with known IGF1 concentrations were
serially diluted, analyzed with the mass spectrometric immunoas-
say to determine the IGF1 concentrations, and the results
compared to those expected (Table 3). Spiking recovery
experiments were also performed by spiking plasma samples,
known to have low IGF1 concentrations, with increasing amounts
of recombinant IGF1, followed by analysis with the assay to
determine the total IGF1 concentration, and comparison of the
results with those expected (Table 4).
For all 1,054 samples, the IGF1 mean concentration and range
was determined (using MSIA) to be 152692 mg/L and range 18–
573 mg/L, respectively, which is consistent with the normal
reference range of IGF1 [3,4]. Fig. 3 shows a histogram
presenting the IGF1 concentration range observed in the
population. Finally, IGF1 ELISA measurements were performed
on 47 representative plasma samples. The IGF1 concentrations
determined with the IGF1 MSIA correlated well with those
obtained with the IGF1 ELISA, with a Passing Bablock fit [29] of
8.40+1.07x and a Cusum linearity test p.0.1. The Bland-Altman
plot [30] shows a slight bias of 16.3% (Fig. 4). This is not unusual,
and it has been observed in a number of method comparison
studies [13,31].
A second aspect of this study was to evaluate practical clinical
viability – as opposed to analytical viability (as just described).
Here, topics of interest may include ease-of-operation, time-to-
data, throughput and cost-of-data. Regarding the first three topics,
we developed and used a simplified sample preparation approach
where SDS was added to plasma to disrupt IGF1/IGFBP
complexes, after which IGF1 (and internal standard) were
Fig. 4. IGF1 methods comparison. A) Scatter plot. B) Difference plot.
doi:10.1371/journal.pone.0092801.g004
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retrieved directly from the resulting solution via immunoaffinity
capture executed in a pipette tip format. As a result, the transfer of
reagents (throughout the overall process) was minimized, and the
IGF1 samples never left the original 96-well microplate, thus
ensuring more accurate IGF1 measurement. Moreover, the
pipette tip extraction format enabled robotic processing (of 96
samples in parallel) of all sample preparation steps – extraction,
rinsing and ‘‘stamping’’ of analyte/matrix mixture onto sample
plates - leading to mass spectrometric analysis. Data acquisition
using MALDI-TOFMS, was rapid, requiring ,30 s per sample
spot to acquire a 5,000 laser shot mass spectrum.
Operating two robot/MS systems realized the analysis of 1,054
clinical samples (plus 96 standard samples) in just over 9 hours
(freezer to data analysis), which equates to a rate of just over 30
seconds per sample. The cost for each analysis (i.e., cost-of-data) is
broken into unit and fixed costs. Unit costs are those incurred
specifically for the analysis, in this case the IGF1 affinity tips,
plastic ware and buffers/reagents. Fixed costs are associated with
having an analytical platform, keeping it operational and using it,
which in this case includes the robot/MS platform, lab space and
manpower. The total cost-of-data for MSIA was ,$11.25, with
unit costs of less than $10 per analysis, and fixed costs of
approximately $1.25. Other MS-based approaches typically
include more involved sample preparation before analysis and
longer times devoted to data acquisition using LC/MS(MS), which
lengthens the time-to-data, reduces throughput and increases costs
(e.g., a 15-minute LC/MS run at $150/hour [32] equates to ,$40
in fixed costs on top of any time needed for sample preparation
and unit costs). However, the cost-of-data (as well as time-to-data
and throughput) demonstrated here is on par, or better than those
of current FDA-Approved IGF1 ELISA approaches (e.g., IDS-
iSYS).
Conclusion
The fundamental components of the IGF1 assay (sample
preparation, immunoaffinity retrieval, and MALDI-TOF MS)
are not novel per se, yet each one contributes significantly to the
overall speed and throughput of the assay, positioning it for
possible clinical use. Today, the current gold standards in IGF1
assaying are enzymatic immunoassays in the form of ELISAs,
which are simple, robust, and affordable. The IGF1 MSIA
demonstrated in this work matches the speed, simplicity and cost
of the ELISA tests, and offers significant improvements (in these
categories) over other reported MS-based IGF1 analyses. More-
over, because MSIA utilizes the very same principle of
immunoaffinity capture that is employed in ELISA, but differs
in the detection of the analyte binding (using direct detection via
high-throughput MALDI-TOFMS instead of ELISAs indirect
detection with a secondary antibody), it is able to aid in
discovering and distinctly monitoring protein microheterogeneity
(e.g. IGF1 A67T) in a single readout. Combined, these charac-
teristics place the mass spectrometric immunoassays at the
doorstep of mainstream clinical and diagnostic use.
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